127-07-1 Hydroxyurea AKSci H792
 
 
Loading Please Wait...
  H792    AKSci Bulk Reagent
Hydroxyurea, 98% (HPLC)
 
Hydroxycarbamide
Hydrea
Biosupressin
IDENTITY
CAS Number:127-07-1
MDL Number:MFCD00007943
MF:CH4N2O2
MW:76.05
EINECS:204-821-7
BRN:1741548
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:142-149°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:H2O: 50mg/mL
Application(s):Inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase
Form:Free Base

REVIEW
 Hydroxyurea is converted to a free radical nitroxide (NO) in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme. The entire replicase complex, including ribonucleotide reductase, is inactivated and DNA synthesis is selectively inhibited, producing cell death in S phase and synchronization of the fraction of cells that survive. Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents. Hydroxyurea also increases the level of fetal hemoglobin, leading to a reduction in the incidence of vasoocclusive crises in sickle cell anemia. Levels of fetal hemoglobin increase in response to activation of soluble guanylyl cyclase (sGC) by hydroxyurea-derived NO.

REFERENCES
[1]Liebelt, E.; Balk, S.; Faber, W.; Fisher, J.; Hughes, C.; Lanzkron, S.; Lewis, K.; Marchetti, F. et al. (2007). NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth defects research. Part B, Developmental and reproductive toxicology 80 (4): 259-366. doi:10.1002/bdrb.20123. PMID 17712860.
[2] Platt OS (2008). Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 358 (13): 1362-9. doi:10.1056/NEJMct0708272. PMID 18367739.
[3] Cokic VP, Smith RD, Beleslin-Cokic BB, et al. (2003). Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 111 (2): 231-9. doi:10.1172/JCI16672. PMC 151872. PMID 12531879.
[4] Harrison CN, Campbell PJ, Buck G, et al. (July 2005). Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353 (1): 33-45. doi:10.1056/NEJMoa043800. PMID 16000354.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H340; H360D; H360Df; H360FD

Precautionary Statements
P201; P202; P281; P405; P503; P501

Current as of April 24, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
⚠️

WARNING: Attention California residents: This product can expose you to chemicals including Hydroxyurea, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.




CATEGORIES
 APIs and Bioactives > Chemotherapeutics


PubChem